46,000 Shares in Arrowhead Pharmaceuticals Inc (ARWR) Acquired by Fosun International Ltd
Fosun International Ltd acquired a new stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 46,000 shares of the biotechnology company’s stock, valued at approximately $551,000.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. BlackRock Inc. increased its stake in Arrowhead Pharmaceuticals by 108.1% in the 2nd quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock valued at $96,342,000 after buying an additional 3,679,986 shares during the period. First Manhattan Co. increased its stake in Arrowhead Pharmaceuticals by 11.6% in the 3rd quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock valued at $96,883,000 after buying an additional 523,675 shares during the period. Vanguard Group Inc increased its stake in Arrowhead Pharmaceuticals by 0.3% in the 3rd quarter. Vanguard Group Inc now owns 3,951,381 shares of the biotechnology company’s stock valued at $75,748,000 after buying an additional 10,273 shares during the period. Vanguard Group Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,951,381 shares of the biotechnology company’s stock worth $75,748,000 after purchasing an additional 10,273 shares in the last quarter. Finally, Vivo Capital LLC boosted its position in shares of Arrowhead Pharmaceuticals by 22.6% during the 3rd quarter. Vivo Capital LLC now owns 2,328,475 shares of the biotechnology company’s stock worth $44,637,000 after purchasing an additional 428,475 shares in the last quarter. 60.45% of the stock is currently owned by institutional investors.
In related news, CEO Christopher Richard Anzalone sold 81,500 shares of the business’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $14.39, for a total value of $1,172,785.00. Following the sale, the chief executive officer now directly owns 1,727,755 shares in the company, valued at approximately $24,862,394.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Douglas B. Given sold 3,000 shares of the business’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $12.74, for a total transaction of $38,220.00. The disclosure for this sale can be found here. Insiders have sold a total of 742,374 shares of company stock worth $10,386,976 over the last 90 days. Insiders own 4.60% of the company’s stock.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, December 11th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. The company had revenue of $11.26 million for the quarter, compared to analyst estimates of $3.73 million. Arrowhead Pharmaceuticals had a negative net margin of 337.32% and a negative return on equity of 57.18%. Equities research analysts forecast that Arrowhead Pharmaceuticals Inc will post 1.49 earnings per share for the current year.
ARWR has been the topic of several research analyst reports. BidaskClub lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Cantor Fitzgerald restated a “buy” rating and set a $24.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 11th. William Blair restated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 17th. Finally, Chardan Capital set a $25.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, October 14th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $21.36.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Article: QQQ ETF
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.